Home » Stocks » PTE

PolarityTE, Inc. (PTE)

Stock Price: $0.690 USD -0.016 (-2.25%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $0.691 +0.001 (0.13%) Dec 3, 7:59 PM

Stock Price Chart

Key Info

Market Cap 27.08M
Revenue (ttm) 8.00M
Net Income (ttm) -53.94M
Shares Out 38.76M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $0.690
Previous Close $0.706
Change ($) -0.016
Change (%) -2.25%
Day's Open 0.704
Day's Range 0.690 - 0.715
Day's Volume 573,855
52-Week Range 0.648 - 4.370

More Stats

Market Cap 27.08M
Enterprise Value 9.56M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.76M
Float n/a
EPS (basic) -1.66
EPS (diluted) -1.57
FCF / Share -1.28
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.78M
Short Ratio 3.62
Short % of Float n/a
Beta 1.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.38
PB Ratio 1.55
Revenue 8.00M
Operating Income -58.66M
Net Income -53.94M
Free Cash Flow -49.78M
Net Cash 17.52M
Net Cash / Share 0.45
Gross Margin 39.65%
Operating Margin -733.04%
Profit Margin -674.10%
FCF Margin -622.09%
ROA -56.09%
ROE -140.20%
ROIC -242.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(334.72% upside)
Current: $0.690
Target: 3.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth261.61%----80.53%-27.29%-64.27%5.58%65.62%-
Gross Profit3.170.56--3.275.7112.1743.5245.4818.39
Operating Income-93.39-69.43-131-4.10-3.93-13.33-12.243.7111.36-2.11
Net Income-92.49-65.44-131-4.64-3.81-16.20-12.644.616.83-0.97
Shares Outstanding24.9715.264.922.
Earnings Per Share-3.70-4.29-26.57-2.21-4.93-15.12-12.784.627.14-1.26
EPS Growth--------35.29%--
Operating Cash Flow-56.65-28.55-7.58-1.77-1.61-3.51-4.596.099.42-3.04
Capital Expenditures-2.77-9.22-2.54-0.29-0.35-0.27-0.34-0.47-0.28
Free Cash Flow-59.42-37.77-10.13-1.77-1.32-3.86-4.865.758.95-3.32
Cash & Equivalents29.2470.9617.676.5217.057.4513.3918.0413.698.00
Total Debt3.521.26----1.76-1.245.56
Net Cash / Debt25.7269.7117.676.5217.057.4511.6218.0412.452.45
Book Value38.9281.660.175.4015.665.5520.0529.3423.2412.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PolarityTE, Inc.
Country United States
Employees 153
CEO Denver Lough

Stock Information

Ticker Symbol PTE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PTE
IPO Date August 13, 1999


PolarityTE, a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.